Results from a Phase 2b, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Early-Stage Parkinson's Disease (MDS Congress 2026) - Sep 19, 2026 - Pres time: Oct 7, 2026; 12:30 PM - 01:30 PM; Location: Conference Room E3, 3rd Floor; No abstract available
Clinical • Late-breaking abstract • P2b data • CNS Disorders • Movement Disorders • Parkinson's Disease
|